Congress Agenda

Monday, 19 February

 07:30  Registration 
 08:30  Congress Opening and Welcome
 08:45  Session I: Keynote Presentations
 09:45  Session II:  Clinical Trials beyond the Patient
  09:45-10:05
Oncology Clinical Trial Operations eg RECIST and Lugano Criteria
Rachel Schor-Bardach, Sheba Medical Center, Israel

10:05-10:25
Personalizing the Micro Environment in Clinical Trials

10:25-10:45
Data Management in Oncology Clinical Trials 
Maria A. CrazeHeadquarters Director of Global Data Operations, Merck & Company, Inc, USA

10:45-11:00
Discussion 
 11:00  Coffee Break, Poster Viewing and visit the Exhibition
 11:30  Session III: Clinical Trials in Hematology 
  Moderator: Clemens Wendtner, Germany

11:30-11:50
The GIMEMA [Gruppo Italiano Malattie Ematologiche dell’Adulto] Framework for Clinical Trials in Hematology in Italy
Marco Vignetti, Director, Central Office, GIMEMA Research Foundation, Rome, Italy

11:50-12:10
The German CLL Study Group
Clemens Wendtner, University of Cologne, Germany

12:10-12:30
The Impact of Clinical Trials in the Management of ALL
Sabina ChiarettiSapienza University of Rome, Italy

12:30-13:00
CAR-T
 13:00 Lunch Break, Poster Viewing and visit the Exhibition
 14:00  Session IV: Finance & Reimbursement in Oncology Clinical Trials 
  14:00-14:30
Pharma Perspective 

14:30-15:00
Pharma Perspective 

15:00-15:30
Panel Discussion 
 15:30  Coffee Break, Poster Viewing and visit the Exhibition
 16:00  Session V: Pre-Clinical Models 
  16:00-16:20
Pre-Clinical Models and How they Influence Clinical Trial Decisions- The Physician Perspective (Pitfalls and Problems) 
Jens Siveke, Director, Division of Solid Tumor Translational Oncology at the partner site Essen of the German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) and Head of the Clinical Pancreatic Cancer Program at the West German Cancer Center, University Hospital Essen, Germany

16:20-16:40
Therapy Trials - Service Company Perspective
Jens Hoffmann, CEO, EPO-Berlin-Buch GmbH, Germany

16:40-17:00
Pre-Clinical Models and How They Influence Clinical Trial Decisions- The Pharma Perspective
Stefanie Loeser, Medical Advisor, Gastrointestinal Oncology, Bristol-Myers Squibb GmbH & Co. KGaA, Germany
 17:00  End of Day One

Tuesday, 20 February 

 08:00 Registration 
 09:00 Session VI: Precision Promise
  Moderator: Victoria Manax, USA

09:00-09:20
Introduction
Victoria Manax, Chief Mediical Officer, Pancreatic Cancer Action Network, USA

09:20-09:50
Precision Promise – A New Paradigm in Clinical Trial Design in Pancreatic Cancer 
Diane SimeoneLaura and Isaac Perlmutter Professor of Surgery and Pathology at New York University and the Director of the Pancreatic Cancer Center at NYU Langone Health, USA
 
09:50-10:20
Engaging Industry Partners in Non-Profit-Led, Innovative Clinical Trials: The Precision Promise Experience
Wendy Selig, Founder & CEO, WSCollaborative, USA

10:20-10:50
Design Innovations in Precision Promise: Adaptive Platform Clinical Trial in Pancreatic Cancer  
Donald Berry, Founder and Co-Owner, Berry Consultants, USA 

10:50-11:00
Discussion
 11:00  Coffee Break, Poster Viewing and visit the Exhibition
 11:30  Session VII: Collaborative Organizations and Clinical Trials
  11:30-12:00
Collaborative Organizations and Clinical Trials - The German Perspective 

12:00-12:30
Collaborative Organizations and Clinical Trials - The French Perspective

12:30-13:00
Collaborative Organizations and Clinical Trials - The Italian Perspective
 13:00  Lunch Break, Poster Viewing and visit the Exhibition
 14:00  Session VIII: Ethics, Patient Advocacy, Audits and Inspections
  14:00-14:30
Ethics in Oncology Trials 

14:30-15:00
Criticism of Clinical Trials

15:00-15:30
Auditing Oncology Clinical Trials: FDA Perspective
Marcia Sherry-Newby, Principal Auditor, Chiltern, USA

15:30-16:00
Patient Advocacy in Clinical Trial Design
 16:00  End of Congress